+

WO2001007611A3 - Novel polynucleotides and method for the use thereof - Google Patents

Novel polynucleotides and method for the use thereof Download PDF

Info

Publication number
WO2001007611A3
WO2001007611A3 PCT/US2000/020006 US0020006W WO0107611A3 WO 2001007611 A3 WO2001007611 A3 WO 2001007611A3 US 0020006 W US0020006 W US 0020006W WO 0107611 A3 WO0107611 A3 WO 0107611A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
polypeptides
novel polynucleotides
antibodies
vectors
Prior art date
Application number
PCT/US2000/020006
Other languages
French (fr)
Other versions
WO2001007611A2 (en
Inventor
Kevin Baker
Audrey Goddard
William Wood
Original Assignee
Kevin Baker
Audrey Goddard
William Wood
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kevin Baker, Audrey Goddard, William Wood filed Critical Kevin Baker
Priority to AU61170/00A priority Critical patent/AU6117000A/en
Priority to EP00947590A priority patent/EP1196570A2/en
Priority to JP2001512880A priority patent/JP2003505082A/en
Priority to CA002378403A priority patent/CA2378403A1/en
Publication of WO2001007611A2 publication Critical patent/WO2001007611A2/en
Publication of WO2001007611A3 publication Critical patent/WO2001007611A3/en
Priority to US10/052,283 priority patent/US20030064379A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to novel polynucleotides and to polypeptides encoded thereby. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
PCT/US2000/020006 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof WO2001007611A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU61170/00A AU6117000A (en) 1999-07-26 2000-07-21 Novel polynucleotides and method of use thereof
EP00947590A EP1196570A2 (en) 1999-07-26 2000-07-21 Human polypeptides and methods for the use thereof
JP2001512880A JP2003505082A (en) 1999-07-26 2000-07-21 Novel polynucleotides and their uses
CA002378403A CA2378403A1 (en) 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof
US10/052,283 US20030064379A1 (en) 1999-07-26 2002-01-15 Novel polynucleotides and method of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14570199P 1999-07-26 1999-07-26
US60/145,701 1999-07-26

Publications (2)

Publication Number Publication Date
WO2001007611A2 WO2001007611A2 (en) 2001-02-01
WO2001007611A3 true WO2001007611A3 (en) 2001-08-23

Family

ID=22514171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020006 WO2001007611A2 (en) 1999-07-26 2000-07-21 Novel polynucleotides and method for the use thereof

Country Status (5)

Country Link
EP (1) EP1196570A2 (en)
JP (1) JP2003505082A (en)
AU (1) AU6117000A (en)
CA (1) CA2378403A1 (en)
WO (1) WO2001007611A2 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021836A2 (en) * 1999-09-23 2001-03-29 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
WO2001023562A2 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoprotegerin regulatory region
JP2003514549A (en) 1999-11-16 2003-04-22 メルク エンド カムパニー インコーポレーテッド G protein-coupled receptor
AU1919401A (en) * 1999-11-17 2001-05-30 Lexicon Genetics Incorporated Novel human notch ligand proteins and polynucleotides encoding the same
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU2001252621A1 (en) * 2000-04-27 2001-11-12 Takeda Chemical Industries Ltd. Novel proetin and use thereof
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040092724A1 (en) * 2000-07-28 2004-05-13 Mcguckin Michael Andrew Mucin
WO2002018556A2 (en) * 2000-08-31 2002-03-07 Millennium Pharmaceuticals, Inc. 8797, a human galactosyltransferase and uses thereof
EP1369478A4 (en) * 2001-02-15 2004-11-17 Mochida Pharm Co Ltd Novel scavenger receptor class a protein
US6518055B2 (en) * 2001-03-26 2003-02-11 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
JP2004535794A (en) 2001-05-03 2004-12-02 チルドレンズ・メディカル・センター・コーポレイション Sperm-specific cation channels and uses thereof
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20020173459A1 (en) * 2001-05-18 2002-11-21 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
CA2449011A1 (en) 2001-05-31 2002-12-05 Merck & Co., Inc. Rhesus monkey, dog and ferret melanin-concentrating hormone type 2 receptor
EP1451333B1 (en) 2001-10-04 2009-06-24 Immunex Corporation Ul16 binding protein 4
US8729248B2 (en) 2001-10-22 2014-05-20 Children's Medical Center Corporation Sperm-specific cation channel, CATSPER2, and uses therefor
JP2005512561A (en) 2001-10-22 2005-05-12 チルドレンズ・メディカル・センター・コーポレイション Sperm-specific cation channel, CATSPER2 and methods of use thereof
ATE427363T1 (en) 2002-01-08 2009-04-15 Novartis Vaccines & Diagnostic GENE PRODUCTS DIFFERENTIALLY EXPRESSED IN CANCER MAMMARY CELLS AND THEIR METHODS OF USE
AU2003258056A1 (en) 2002-08-07 2004-02-25 Children's Medical Center Corporation Sperm-specific cation channel, catsper-3, and uses therefor
US20060123497A1 (en) 2002-08-07 2006-06-08 Children's Medical Center Corporation Sperm-specific cation channel, catsper-4, and uses therefor
MXPA05004739A (en) 2002-11-06 2005-08-02 Tularik Inc Fused heterocyclic compounds.
EP2093298A3 (en) 2003-10-10 2009-09-23 Deutsches Krebsforschungszentrum Compositions for diagnosis and therapy of diseases associated with aberrant expression of Futrins (R-Spondins)
GB0417887D0 (en) 2004-08-11 2004-09-15 Ares Trading Sa Protein
DK3428191T3 (en) 2004-10-06 2025-01-02 Mayo Found Medical Education & Res B7-H1 AND PD-1 FOR THE TREATMENT OF RENAL CELL CARCINOMA
EP2562188A3 (en) 2006-09-29 2013-03-06 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2997975A1 (en) 2006-10-20 2016-03-23 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
PL3009148T3 (en) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2010121923A1 (en) 2009-04-15 2010-10-28 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US8802097B2 (en) 2011-07-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Anti-RSPO1 antibodies
MX2015000565A (en) 2012-07-13 2015-04-10 Oncomed Pharm Inc Rspo3 binding agents and uses thereof.
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
TW202035447A (en) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 Novel bispecific agonistic 4-1bb antigen binding molecules
TWI818387B (en) 2018-12-21 2023-10-11 瑞士商赫孚孟拉羅股份公司 Antibodies binding to cd3
CN113272327A (en) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 Anti-rabbit CD19 antibodies and methods of use thereof
BR112021014276A2 (en) 2019-01-22 2021-09-28 Genentech, Inc. ISOLATED IGA ANTIBODIES, ISOLATED IGG-IGA FUSION MOLECULES, ISOLATED NUCLEIC ACID, HOST CELL, METHOD FOR PRODUCING AN ANTIBODY, TO TREAT AN INDIVIDUAL, TO INCREASE THE EXPRESSION OF DIMERS, TRIMERS OR TETRAMERS, TO INCREASE THE PRODUCTION OF POLYMERS, TO INCREASE The production of dimers, to increase the production of a polymer, to decrease the production of polymers, to increase the transient expression of an antibody, to express dimers of fusion molecules, to express dimers, trimers or tetramers, to purify an antibody, TO PURIFY AN OLIOMER STATE OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY
JP2022522197A (en) 2019-02-28 2022-04-14 ジェネンテック， インコーポレイテッド Antibacterial peptides and usage
WO2020208049A1 (en) 2019-04-12 2020-10-15 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising lipocalin muteins
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
AR119393A1 (en) 2019-07-15 2021-12-15 Hoffmann La Roche ANTIBODIES THAT BIND NKG2D
KR20220064980A (en) 2019-09-18 2022-05-19 제넨테크, 인크. Anti-KLK7 Antibodies, Anti-KLK5 Antibodies, Multispecific Anti-KLK5/KLK7 Antibodies, and Methods of Use
KR20220100963A (en) 2019-12-18 2022-07-18 에프. 호프만-라 로슈 아게 Antibodies that bind to HLA-A2/MAGE-A4
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
AU2020412609A1 (en) 2019-12-23 2022-06-16 Genentech, Inc. Apolipoprotein L1-specific antibodies and methods of use
KR20230020975A (en) 2020-06-08 2023-02-13 에프. 호프만-라 로슈 아게 Anti-HBV Antibodies and Methods of Use
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
JP2023538716A (en) 2020-06-19 2023-09-11 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibodies that bind to CD3 and CD19
JP2023531625A (en) 2020-06-19 2023-07-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibodies that bind CD3 and FolR1
IL296089A (en) 2020-06-19 2022-11-01 Hoffmann La Roche Antibodies bind to cd3
MX2022015203A (en) 2020-06-19 2023-01-05 Hoffmann La Roche Immune activating fc domain binding molecules.
CN115867583A (en) 2020-07-10 2023-03-28 豪夫迈·罗氏有限公司 Antibodies that bind to cancer cells and target radionuclides to said cells
CA3185122A1 (en) 2020-07-17 2022-01-20 Cecilia Pui Chi Chiu Anti-notch2 antibodies and methods of use
CR20230045A (en) 2020-08-03 2023-02-21 Hoffmann La Roche ENHANCED ANTIGEN BINDING RECEPTORS
IL300024A (en) 2020-10-20 2023-03-01 Hoffmann La Roche Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
AR123855A1 (en) 2020-10-20 2023-01-18 Genentech Inc PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE
AR124562A1 (en) 2020-10-28 2023-04-12 Hoffmann La Roche ENHANCED ANTIGEN BINDING RECEPTORS
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
EP4277705A1 (en) 2021-01-12 2023-11-22 F. Hoffmann-La Roche AG Split antibodies which bind to cancer cells and target radionuclides to said cells
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
EP4304732A1 (en) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
BR112023023777A2 (en) 2021-05-14 2024-01-30 Genentech Inc ISOLATED ANTIBODIES, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEIC ACID, ISOLATED VECTOR, ISOLATED HOST CELL, METHOD FOR PRODUCING AN ANTIBODY, METHOD FOR TREATING A CONDITION ASSOCIATED WITH LOSS OF TREM2 FUNCTION, METHOD FOR REDUCING STREM2 LEVELS AND USE OF AN ANTIBODY
IL308015A (en) 2021-06-09 2023-12-01 Hoffmann La Roche Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
EP4370545A1 (en) 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
WO2023288241A1 (en) 2021-07-14 2023-01-19 Genentech, Inc. Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
AU2022315528A1 (en) 2021-07-22 2023-10-19 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CR20240220A (en) 2021-11-25 2024-07-19 Hoffmann La Roche ENHANCED ANTIGEN BINDING RECEPTORS
AR127887A1 (en) 2021-12-10 2024-03-06 Hoffmann La Roche ANTIBODIES THAT BIND CD3 AND PLAP
CN118401546A (en) 2021-12-15 2024-07-26 基因泰克公司 Stabilized IL-18 polypeptides and uses thereof
CR20240246A (en) 2021-12-20 2024-07-19 Hoffmann La Roche AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM
US20230322958A1 (en) 2022-01-19 2023-10-12 Genentech, Inc. Anti-Notch2 Antibodies and Conjugates and Methods of Use
EP4493936A1 (en) 2022-03-14 2025-01-22 F. Hoffmann-La Roche AG Modulators of the g3bp2-tau interaction for the treatment of tau associated diseases
WO2023180511A1 (en) 2022-03-25 2023-09-28 F. Hoffmann-La Roche Ag Improved chimeric receptors
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
AR128876A1 (en) 2022-03-28 2024-06-19 Hoffmann La Roche ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES
EP4504780A1 (en) 2022-04-01 2025-02-12 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4508206A1 (en) 2022-04-12 2025-02-19 F. Hoffmann-La Roche AG Fusion proteins targeted to the central nervous system
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL318216A (en) 2022-07-13 2025-03-01 Genentech Inc Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en) 2022-07-19 2024-01-25 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
IL317637A (en) 2022-07-22 2025-02-01 Genentech Inc Anti-steap1 antigen-binding molecules and uses thereof
WO2024068572A1 (en) 2022-09-28 2024-04-04 F. Hoffmann-La Roche Ag Improved protease-activatable t cell bispecific antibodies
TW202421664A (en) 2022-10-07 2024-06-01 美商建南德克公司 Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
TW202426505A (en) 2022-10-25 2024-07-01 美商建南德克公司 Therapeutic and diagnostic methods for cancer
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024206788A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024231320A1 (en) 2023-05-08 2024-11-14 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules
WO2025049876A1 (en) 2023-09-01 2025-03-06 Genentech, Inc. Methods for treating inflammatory bowel disease
WO2025068207A1 (en) 2023-09-25 2025-04-03 F. Hoffmann-La Roche Ag ANTIBODY THAT BINDS TO C3bBb

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
EP0834563A2 (en) * 1996-09-26 1998-04-08 Smithkline Beecham Corporation Human 7-transmembrane receptor, member of the chemokine receptor family, named Strl-33

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (en) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Dna sequences and secreted proteins encoded thereby
EP0834563A2 (en) * 1996-09-26 1998-04-08 Smithkline Beecham Corporation Human 7-transmembrane receptor, member of the chemokine receptor family, named Strl-33

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMHTG23 EMBL Heidelberg, Germany; 31 March 2000 (2000-03-31), HATTORI M ET AL.: "Homo sapiens 177,097 genomic DNA of 18q21", XP002152825 *
DATABASE EMHUM1 EMBL Heidelberg, Germany; 15 March 1999 (1999-03-15), BIRREN B ET AL.: "Homo sapiens chromosome 18, clone hRPK.411_H_24", XP002152824 *

Also Published As

Publication number Publication date
AU6117000A (en) 2001-02-13
JP2003505082A (en) 2003-02-12
CA2378403A1 (en) 2001-02-01
WO2001007611A2 (en) 2001-02-01
EP1196570A2 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
WO2001007611A3 (en) Novel polynucleotides and method for the use thereof
WO1999028462A3 (en) Polypeptides and nucleic acids encoding the same
WO2001016318A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001040466A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000053756A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000077037A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999063088A8 (en) Membrane-bound proteins and nucleic acids encoding the same
WO1999061469A3 (en) Prostate growth-associated membrane proteins
WO2001068848A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008288A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999014328A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000032776A3 (en) Secreted amd transmembrane polypeptides and nucleic acids encoding the same
WO2002024888A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3774300A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001046420A8 (en) Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2000015796A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000036102A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000056889A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000068376A8 (en) Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2003076569A3 (en) Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
EP1241179A3 (en) Human cornichon-like protein and nucleic acids encoding it
KR100515858B1 (en) PRO617 Polypeptides
EP1241187A3 (en) Fibilin-like polypeptide and nucleic acids encoding the same
EP1251139A3 (en) Human mindin-like protein and nucleic acids encoding it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2378403

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000947590

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000947590

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000947590

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载